Lectures & Orals Jimenez
Invited lectures at international meetings
Invitations 2019: European Proteomics Association EUPA2019, march.Potsdam, Germany 44th FEBS congress, Krakow, Poland
EuPA2018, “Translating Genomes into Biological Functions” Santiago de Compostela, Spain, 29 June 2018. Title: “(Phospho)Proteomics for marker and target discovery in cancer”
ProteoRed Plataformas tecnológicas y “big data” aplicados a la medicina de precisión. El Escorial, Spain, 27 July, 2018. Title: “Phosphoproteomics, towards precision oncology”
2018 Analytica, Symposium Personalized Medicine, Munich, Germany, 11 April 2018. Title: Large-scale label-free clinical proteomics with a focus on cancer
2016 ProteoRed Reunion Proteomica Clinica, Valencia, Spain 30 Nov. 2016. Title: Clinical proteomics in translational colorectal cancer research
2017 SEPROT, Clinical Proteomics, La Coruna, Spain, 25 Oct. 2017. Title: Clinical proteomics with a focus on cancer.
2016 Conference Cancer Stem Cells: Impact on Treatments, Obergurgl, Austria, 9 Dec. 2016. Title: (Phospho)Proteomics to uncover tumor biology, biomarkers and drug targets
2016 VII Reunión Científica sobre Proteómica Clínica, Valencia, Spain, 30 Nov. 2016. Title: Clinical proteomics in translational colorectal cancer research
2015 14th Human Proteome Organisation Worl Congress, 28 sept. 2016, Vancouver USA. Title: Integrative Analysis of the Colorectal Cancer Proteome and Its Subtypes with Differential Prognosis
2014 Human Proteome Organisation (HUPO) 2014, Madrid, Spain, Invited speaker (7 okt. 2014); Title: From (colon) cancer proteomics to biomarkers, drug targets and clinical applications
2014 American Society Clinical Oncology (ASCO), Invited speaker and session chair at the educational session on Cancer Proteomics (June 2014)
2013 7th European Summerschool Advanced proteomics (9 aug. 2013, Brixen, Italy); Title: “Cancer Proteomics”
2013 HUPO2013 (sept., Japan); Title: “Label-free proteomics for biomarker discovery and validation in proximal fluids”
2012 2nd workshop Biomarkers in the early diagnosis of neurodegenerative disorders. (8 juni 2012, Assisi, Italy); Title: “New CSF biomarkers for AD: report from the cNEUPRO discovery phase”
2012 19th Arbeitstagung Micromethods in Protein Chemistry (26 June, 2012 Bochum); Title: “Cancer biomarker discovery and validation: Label-free mass spectrometry-based proteomics”
2011 SEPROT 2011, 11 feb. Segovia. Title: ‘Label-free mass spectrometry-based proteomics for biomarker discovery and validation in tissues and biofluids’
2011 Cancer Proteomics 20 juni 2011: Systems Biology, Developmental Models and Data Integration, Dublin. Title: “Label-free mass spectrometry-based proteomics for biomarker discovery in murine and human cancer"
2011 AAICAD 20 juli 2011, Paris. Title: “Progress in CSF biomarker discovery for mild cognitive impairment and Alzheimer’s Disease by label-free quantitative proteomics”
2011 Multidisciplinary European Cancer Congress, 25 sept. Stockholm. Title: “Label-free mass spectrometry-based proteomics for biomarker discovery and validation in tissues and biofluids”
2011 Annual CTMM meeting, 29 sept. Utrecht. Title: “Protein biomarkers for cisplatin treatment response prediction in non-small cell lung cancer”
2011 Freiburg, 10 okt. Title: “Label-free mass spectrometry-based proteomics for biomarker discovery in murine and human cancer"
2010 Heraklion, Greece, 8 Oct. “1st International Proteomics Conference on Crete – IPCC01”. Title: ‘Label-free proteomics targeted to sub-cellular compartments for candidate biomarker discovery and early detection of colorectal cancer”
2010 Assisi, Italy, 4 june. “Workshop on Biomarkers in the early diagnosis of neurodegenerative disorders”. Title: ‘’CSF proteomics for biomarker discovery in mild cognitive impairment and Alzheimer’s disease’’
2010 Aberdeen, Ireland, 13 april. Symposium “Advanced Proteomic Applications in Clinical and Life Sciences”. Title: ‘Targeted mass spectrometry-based proteomics strategies for biomarker discovery and validation in colorectal cancer’.
2010 Seatlle, USA, 23 march, International Cancer Biomarker Consortium Conference, Title: ‘’Targeted Mass Spectrometry-based Proteomics Strategies for Biomarkers Discovery and Validation in Colorectal Cancer’’
2009 Brussel, EORTC PAM group meeting, 17 march. Title: ‘Proteomics targeted to sub-cellular fractions for biomarker discovery in colorectal cancer’
2009 Bonn, 7 may. Novel tool for cancer risk meeting, German Cancer Aid, Title:’Proteomics targeted to sub-nuclear compartments and secretomes for biomarker discovery in colorectal cancer’
2009 EMBO Cancer Proteomics 2009, Dublin. Title:‘Proteomics targeted to sub-cellular fractions for biomarker discovery in colorectal cancer’
2009 9th Mass spectrometry in the health and Life sciences, San Francisco, USA, 24 aug. Title: ‘Proteomics targeted to sub-cellular fractions for biomarker discovery in colorectal cancer’
2009 33th meeting of the international Society of Oncology and Biomarkers, Amsterdam, 29 sept. Tiltle: ‘Proteomics targeted to sub-cellular compartments for candidate biomarker discovery in colorectal cancer’.
2008 HUPO2008, Amsterdam, Title: ‘Proteomics targeted to sub-nuclear compartments for discovery of signalling pathways in colorectal cancer’
2008 Applied Biosystems proteomics symposium. Uppsala. Sweden. ‘Mass spectrometry-based sub-cellular proteomics for cancer biomarker discovery’
2008 International Society of Cellular Oncology (ISCO) 2008 meeting. Amsterdam. Proteomics targeted to sub-cellular compartments and secretomes for candidate biomarker discovery in colorectal cancer.
2007 Fall meeting, Danish Proteomics Society. Proteomics targeted to sub-cellular compartments and secretomes for cancer biomarker discovery
2007 3rd BioMS meeting, London. Pre-analytical variables in CSF sample handling
2007 HUPO2007 (Human Proteome Organisation). Seoul. South Korea. Glioblastoma membrane proteomics in a rat xenograft model
2007 4th Munster Single Cell Meeting. Munster. From mass spectrometric peptide profiling of single neurons towards imaging mass spectrometry
2006 2nd Norwegian Proteomics Meeting, Bergen, Norway. Mass spectrometry-based biomarker discovery.
2005 12th European Congress of Biotechnology, Copenhagen, Denmark. Proteomics of the regenerating peripheral nerve after injury.
2004 Joint meeting of the Pathological Society of Great Brittain and the Dutch Pathological Society, Amsterdam, The Netherlands. Title: “Proteomics in Pathology”
2002 Polish Institute for Biochemistry and Biophysics, Warsaw, Poland. Title: “Peptidomics and proteomics in the neurosciences”
2002 Proteomics Technology Forum, Heidelberg, Germany. Title: “Peptidomics and proteomics strategies to analyze post-translantional modifications”
2001 Leibniz Institute for Neurobiology. Magdeburg, Germany. Title: “Proteomic analysis of lesion-induced changes in protein expression patterns of regenerating rat sciatic nerve”
2000 Pan European Proteomics Seminar Tour. Brussels, Belgium. Title: ‘Functional proteomics analysis of neurotrophin signal transduction and neuroregeneration.’
1997 17th International Congress of Biochemistry and Molecular Biology, San Francisco, California. Minisymposium on Mass Spectrometry. Title: ‘MALDI tandem mass spectrometry for the direct qualitative and semi-quantitative analysis of neuropeptides in single cells and tissue.’
1994 Third International Symposium on Mass Spectrometry in the Health and Life Sciences, San Francisco, California. Title: ‘Direct neuropeptide profiling of single neurons and target tissue by matrix-assisted laser desorption/ionization mass spectrometry.’
Invited lectures at national meetings
2016 Phaedra consortium, Bloemendaal, 29 Sept. 2016. Title: OncoProteomics: Towards improved early diagnostics and treatment for cancer.
2015 Symposium of the Center for Personalized Cancer Treatment (29 Oct. 2015, Utrecht); Title: (Phospho)Proteomics complementing the CPCT genomics-based personalized treatment effort with the functionally relevant –OME.
2014 Symposium of the Center for Personalized Cancer Treatment (9 Oct. 2014, Utrecht); Title: (Phospho)Proteomics, pathways, biomarkers
2013 Netherlands Proteomics Center 10-year anniversary meeting (11 Feb. 2013 Utrecht); Cancer Proteomics: Novel biomarkers for colon cancer screening and BRCA1 deficient breast cancer
2013 7 maart 2013, PAC Imagine symposium, Amsterdam; From peptidomics to proteomics, a personal view of 25 years of label-free mass spectrometry
2012 NBIC, Hot topics day (5 March. 2012, Utrecht); Peptide and protein quantification using Mass Spectrometry. “Label-free mass spectrometry-based proteomics for cancer biomarker discovery, Protein quantitation by spectral counting: A pragmatic perspective”
2012 NUBIN2012 symposium (15 juni 2012, Amsterdam); “New CSF biomarkers for AD: report from the cNEUPRO discovery phase”
2011 EndoNeuroPsycho meeting, ENP 30 mei 2011. Lunteren. CSF proteomics reveals pathogenesis and novel candidate biomarkers for mild cognitive impairment and Alzheimer’s Disease
2010 28 Oct, Amsterdam, The Netherlands. Annual meeting Nederlandse Vereniging voor Massaspectrometrie: ‘’Mass spectrometry in aMSterdam’. Title: ‘’Label-free mass spectrometry-based proteomics for biomarker discovery and validation in tissues and biofluids’’
2008 NUBIN symposium, Amsterdam. Title: ‘Strategies for CSF biomarker discovery’
2007 6th Dutch Endo-Neuro-Psycho Meeting 2007 (ENP2007). Doorwerth. Native peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry
2007 Genomics Researchers Event (NGI) Amsterdam. Proteomics: from biological discovery to candidate biomarker
2007 7th Fall meeting of the Netherlands Proteomics Platform, Amsterdam. Subnuclear proteomics for cancer biomarker discovery
2006 2nd NUBIN biomarker symposium. Amsterdam. Mass spectrometry-based biomarker discovery.
2005 Lustrum meeting of the Netherlands Proteomics Platform. Den Haag. Proteomics of protein complexes isolated by immune precipitation.
2005 Biotech Roadshow, Amsterdam. From mass spectrometric peptide profiling of single cells and biofluids to direct imaging of neuropeptides in tissue slices.
2002 Erasmus Lectures on Endocrinology, Rotterdam, The Netherlands. ‘Neuropeptidomics’: Semi-quantitative profiling of neuropeptides in single cells, tissues and releasates using mass spectrometry.
2001 Spring Meeting Nederlandse Vereniging voor Massaspectrometrie. Wageningen, The Netherlands. ‘Proteomic and peptidomic analyses in the neurosciences.’
2001 Fifth Dutch Endo-Neuro Meeting. Doorwerth, The Netherlands. ‘Proteomic analysis of lesion-induced changes in protein expression patterns of regenerating rat sciatic nerve.’
1995 Annual Meeting of the Society for Comparative Endocrinology, Doorwerth, The Netherlands. ‘Peptide diversity in single cardiorespiratory neurons of the mollusc Lymnaea stagnalis: a structural and functional characterization’.
Oral presentations (selected from submitted abstracts)
2017 HUPO2018, Dublin, Ireland, 18 Sept. 2017. Title: Platelet proteomics: towards non-invasive cancer detection.
2013 International Society of Extracllular Vesicles (ISEV) meeting (18 april, Boston); Title: “Proteomics of Exosomes Secreted by Cancer Cell lines and Primary Cells Reveals Oncogenic Signalling and Biomarker Potential”
2009 21 april, 2009, Denver, AACR. Title: ‘Targeted proteomics of sub-nuclear compartments for discovery of signalling pathways and candidate biomarkers in colorectal cancer’
2006 European Biomarker Summit, Prague. Title: “Automated serum peptide profiling using novel C18 magnetic beads off-line coupled to MALDI-TOF mass spectrometry”
2001 49th ASMS conference on Mass Spectrometry and Allied Topics, Chicago, USA. Title: ‘Proteomic analysis of lesion-induced changes in protein expression patterns of regenerating rat sciatic nerve.’
1995 NATO Advanced Study Institute on Mass Spectrometry in Biomolecular Sciences, Altavilla Milicia, Italy.Title: ‘Differential display of pituitary peptide after salt-loading by means of direct matrix-assisted laser desorption mass spectrometric profiling’.
1995 Annual Meeting of the Society for Neuroscience, San Diego, California. Title: ‘Differential display of pituitary peptides using semi-quantitative mass spectrometric profiling’.